title: Disruption of orofacial movement topographies in congenic mutants with dopamine D5 but not D4 receptor or DARPP-32 transduction 'knockout'.
abstract: The role of D(1)-like [D(1), D(5)] and D(2)-like [D(2), D(3), D(4)] dopamine receptors and dopamine transduction via DARPP-32 in topographies of orofacial movement was assessed in restrained mice with congenic D(4) vs. D(5) receptor vs. DARPP-32 'knockout'. D(4) and DARPP-32 mutants evidenced no material phenotype; also, there were no alterations in topographical responsivity to either the selective D(2)-like agonist RU 24213 or the selective D(1)-like agonist SK and F 83959. In contrast, D(5) mutants evidenced an increase in spontaneous vertical jaw movements, which habituated more slowly than in wildtypes, and a decrease in horizontal jaw movements; topographical responsivity to SK and F 83959 and RU 24213 was unaltered. D(5) receptors regulate distinct topographies of vertical and horizontal jaw movement in an opposite manner. In assuming that the well-recognised role of the D(1)-like family in regulating orofacial movements involves primarily D(1) receptors, a role for their D(5) counterparts may have been overlooked.
authors.affiliation: Nihon University Advanced Research Institute for the Sciences and Humanities, Tokyo 102, Japan.
authors.forename: Katsunori
authors.initials: K
authors.lastname: Tomiyama
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Makihara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Gerard
authors.initials: G
authors.lastname: O'Sullivan
authors.forename: Rachel E
authors.initials: RE
authors.lastname: Nally
authors.forename: Orna
authors.initials: O
authors.lastname: Tighe
authors.forename: Anthony
authors.initials: A
authors.lastname: Kinsella
authors.forename: Allen A
authors.initials: AA
authors.lastname: Fienberg
authors.forename: David K
authors.initials: DK
authors.lastname: Grandy
authors.forename: David R
authors.initials: DR
authors.lastname: Sibley
authors.forename: David T
authors.initials: DT
authors.lastname: Croke
authors.forename: Noriaki
authors.initials: N
authors.lastname: Koshikawa
authors.forename: John L
authors.initials: JL
authors.lastname: Waddington
mesh_terms: D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D002839:Chromans / Q000494:pharmacology; D051937:Dopamine and cAMP-Regulated Phosphoprotein 32 / Q000172:deficiency / Q000235:genetics*; D004409:Dyskinesia, Drug-Induced / Q000235:genetics* / Q000503:physiopathology; D051379:Mice; D020297:Mice, Congenic; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D050638:Receptors, Dopamine D4 / Q000819:agonists / Q000172:deficiency / Q000235:genetics*; D050641:Receptors, Dopamine D5 / Q000819:agonists / Q000172:deficiency / Q000235:genetics*; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics*
chemical_list: D002839:Chromans; D051937:Dopamine and cAMP-Regulated Phosphoprotein 32; C493600:Drd4 protein, mouse; C497929:Ppp1r1b protein, mouse; D050638:Receptors, Dopamine D4; D050641:Receptors, Dopamine D5; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; C080703:SK&F 83959; C065380:A 68930